OSE Immunotherapeutics Announces Results of 2019 Annual Shareholder Meeting

Regulatory News:

OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today announced that all the resolutions submitted to a vote at the Combined General Shareholders' Meeting were approved as proposed by OSE Immunotherapeutics’ Board of Directors.

The results of each voted-upon resolution can be found on the Company’s website in the “Investor – General Shareholders’ Meeting” section (https://ose-immuno.com/general-shareholders-meetings/).

A total of 78 shareholders were present or represented or voted by mail. Collectively, this group holds 9,003,075 shares (representing 60.93 % of the share capital) and 13,626,575 voting rights (representing 66.96 % of voting rights).

The Company’s shareholders have approved the appointment of Nicolas Poirier, Ph.D. as director, representing the employee shareholders.

Nicolas Poirier has been chief scientific officer of OSE Immunotherapeutics since 2016. He joined the company in 2009 as project leader and then as director of scientific programs. Nicolas holds a Ph.D. in immunology and has a strong expertise in the development of immunotherapies. His role at OSE has been to implement innovative therapeutic strategies on new targets and pathways in immunology addressing severe pathologies with high therapeutic need, thus making a robust contribution to the Company’s growth. Along with his R&D team, Dr. Poirier continues pursuing the identification of novel preclinical targets and translating them into first-class clinical-stage immunotherapies. He is the author of several high-level international publications in the area of immunotherapy.

During the meeting, Dominique Costantini, Chairman, and Alexis Peyroles, CEO of OSE Immunotherapeutics, provided an overview of the Company’s latest advances and growth strategy.

“OSE Immunotherapeutics has continued to move forward its exciting clinical pipeline in immuno-oncology and autoimmune diseases in 2019. We continue to explore opportunities for our lead product, Tedopi, and for Phase 2-ready FR104 and are very pleased with the progression of partnered drug candidates BI 765063 and OSE-127. These are very interesting products which bring validation to our approach, through the partnerships with Boehringer Ingelheim and Servier, and are already generating important milestone payments for OSE,” commented Alexis Peyroles.